小脑
化学
泛素连接酶
蛋白质水解
受体
蛋白酶体
泛素
细胞生物学
生物化学
生物
基因
酶
作者
Fei Meng,Chenxi Xu,Kwang‐Su Park,H. Ümit Kaniskan,Gang Greg Wang,Jian Jin
标识
DOI:10.1021/acs.jmedchem.2c00807
摘要
Overexpression of nuclear receptor binding SET domain protein 2 (NSD2) is frequent in multiple myeloma (MM). However, existing NSD2 inhibitors are largely ineffective in suppressing MM cell proliferation. Here, we report the discovery of a first-in-class NSD2 proteolysis targeting chimera (PROTAC) degrader, 9 (MS159), and two structurally similar controls, 17 (MS159N1) and 18 (MS159N2), with diminished binding to the cereblon (CRBN) E3 ligase and NSD2, respectively. Compound 9, but not 17 and 18, effectively degraded NSD2 in a concentration-, time-, CRBN-, and proteasome-dependent manner. Compound 9 also effectively degraded CRBN neo-substrates IKZF1 and IKZF3, but not GSPT1. Importantly, compound 9 was much more effective in suppressing the growth in cancer cells than the parent NSD2 binder. Moreover, compound 9 was bioavailable in mice. Altogether, compound 9 and its two controls 17 and 18 are valuable chemical tools for exploring the roles of NSD2 in health and disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI